Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis†
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Hepatic fibrosis and cirrhosis are possible consequences of corticosteroid-treated autoimmune hepatitis. Our aims were to determine the frequency of progressive fibrosis and the factors associated with this progression. Two hundred seventy-seven liver tissue specimens that had been obtained from 73 patients were interpreted in batch under code by a single pathologist. Fibrosis scores and histological activity indices were determined using the Ishak scoring system, and worsening fibrosis scores were correlated with clinical features, laboratory findings, and treatment responses. Fibrosis scores increased (2.3 ± 0.4 points to 4.2 ± 0.4 points; P < .0001) in 18 patients (25%) during 79 ± 13 months. Only five patients (7%) developed cirrhosis, and 55 patients (75%) had stable (16 patients) or decreased (39 patients) fibrosis scores. Human leukocyte antigen (HLA) DR3/DR4 occurred more frequently in patients with progressive fibrosis than others (23% vs. 2%; P = .03). Patients with progressive fibrosis had higher histological activity indices at last follow-up than patients with stable or reduced fibrosis (3.2 ± 0.7 vs. 1.7 ± 0.2; P = .01), and these indices worsened more commonly during therapy (17% vs. 2%, P = .04). Relapse, treatment failure, and incomplete response did not affect progression of fibrosis. In conclusion, fibrosis progresses in only a minority of patients during corticosteroid therapy. Progression is associated with HLA DR3/DR4 and worsening histological activity. Exacerbations or persistence of disease activity does not increase disease progression after treatment has been instituted. (Hepatology 2004;39:1631-1638.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alvarez, F., Berg, P. A., Bianchi, F. B., Bianchi, L., Burroughs, A. K., Cancado, E. L., Chapman, R. W., Cooksley, W. G. E., Czaja, A. J., Desmet, V. J., et al. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80297-9 · Cited by 2,903
Self-citationIredale, J. P., Benyon, R. C., Pickering, J., McCullen, M., Northrop, M., Pawley, S., Hovell, C., & Arthur, M. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1018 · Cited by 1,075 · cited 1×
“1 Immunoglobulin G (nL, 600–1,500 mg/dL) 3100 155 SMA-positive 19 (26) ANA-positive 11 (15) SMA- and ANA-positive 43 (59) HLA DR3 /DR4 25/60 (42) HLA DR4 /DR3 21/60 (35) HLA DR3 /DR4 4/60 (7) HLA DR3 and/or DR4 50/60 (83)”
Murphy, F. R., Issa, R., Zhou, X., Ratnarajah, S., Arthur, M. J. P., Benyon, C., Iredale, J. P., & Nagase, H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111490200 · Cited by 432 · cited 1×
“7 HLA DR3 /DR4 4/13 (31) 4/10 (40) 21/47 (45) HLA DR4 /DR3 4/13 (31) 2/10 (20) 17/47 (36) HLA DR3 /DR4 3/13 (23)* 3/10 (30)† 1/47 (2)*,† HLA DR3 /DR3 1/13 (8) 1/10 (10) 7/47 (15) HLA DR4 /DR4 0/13 (0) 0/5 (0) 4/47 (8)”
Cited by
Autoimmune Hepatitis: Effect of Symptoms and Cirrhosis on Natural History and Outcome *
Feld, J. J., Dinh, H., Arenovich, T., Marcus, V. A., Wanless, I. R., & Heathcote, J. E. (2005) · Hepatology · doi:10.1002/hep.20732 · Cited by 367
Tsukada, S., Parsons, C. J., & Rippe, R. A. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.06.014 · Cited by 357
Friedman, S. L. (2008) · Toxicology · doi:10.1016/j.tox.2008.06.013 · Cited by 350
Hepatic inflammation and progressive liver fibrosis in chronic liver disease
Czaja, A. J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i10.2515 · Cited by 342
Self-citationEvidence-based clinical practice guidelines for liver cirrhosis 2015
Fukui, H., Saito, H., Ueno, Y., Uto, H., Obara, K., Sakaida, I., Shibuya, A., Seike, M., Nagoshi, S., Segawa, M., et al. (2016) · Journal of Gastroenterology · doi:10.1007/s00535-016-1216-y · Cited by 306
British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis
Gleeson, D., & Heneghan, M. A. (2011) · Gut · doi:10.1136/gut.2010.235259 · Cited by 275
Drug-induced autoimmune-like hepatitis
Czaja, A. J. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1611-4 · Cited by 235
Self-citationAgarwal, K., Czaja, A. J., & Donaldson, P. T. (2007) · Tissue Antigens · doi:10.1111/j.1399-0039.2006.00794.x · Cited by 86
Self-citationYang, Y., Wu, X.-Q., Li, W.-X., Huang, H.-M., Li, H.-D., Pan, X.-Y., Li, X.-F., Huang, C., Meng, X.-M., Zhang, L., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0383-0 · Cited by 72
Metadata
- Authors
- Czaja, A. J., & Carpenter, H. A.
- Venue
- Hepatology
- Published
- 2004-06
- Volume
- 39
- Issue
- 6
- Pages
- 1631-1638
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1997331891
- Cited by
- 127
- References
- 3
- FWCI
- 5.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.